Physician profile
Venkatachala Mohan
NPI 1194704106
$564,477.99
in general payments reported to CMS, 2019-2025
49 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $54K · 2021: $87K · 2022: $53K · 2023: $69K · 2024: $124K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $190K · Travel and Lodging: $28K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Consulting Fee: $8,088 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,128.00 |
| Travel and Lodging | $27,632.42 |
| Food and Beverage | $21,837.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,550.00 |
| Consulting Fee | $8,087.50 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213,002.11 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $125,700.05 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119,888.95 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $60,765.65 | 2021-2024 | Zeposia |
| Allergan, INC. | $21,525.11 | 2019-2020 | |
| Celgene Corporation | $5,540.24 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $2,543.98 | 2019-2025 | Tremfya, Stelara |
| Redhill Biopharma INC. | $2,311.90 | 2020-2021 | |
| Genzyme Corporation | $2,117.09 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,005.98 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Boston Scientific Corporation | $1,477.50 | 2019-2025 | X-Tack Endoscopic Helix Tacking System |
| Pfizer INC. | $1,384.31 | 2019-2025 | |
| Ardelyx, INC. | $642.19 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $611.41 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $456.78 | 2024-2025 | Zenpep, Vowst |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $436.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $275.70 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $271.14 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $261.48 | 2025 | Zymfentra, Vegzelma |
| Amgen INC. | $251.22 | 2021-2024 | Tavneos, Amjevita, Avsola |
| Lilly USA, LLC | $251.09 | 2023-2025 | Omvoh, Jardiance |
| Organon LLC | $224.88 | 2022-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $202.85 | 2022-2024 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $199.67 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $185.26 | 2024-2025 | Iqirvo, Bylvay |
| Ferring Pharmaceuticals INC. | $183.74 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $183.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $171.81 | 2019-2025 | Dificid, Bridion |
| Novo Nordisk INC | $136.36 | 2019-2025 | Wegovy |
| Davol INC. | $125.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2025 | |
| Intercept Pharmaceuticals, INC. | $121.98 | 2019-2024 | Ocaliva |
| Daiichi Sankyo INC. | $118.82 | 2019-2025 | Injectafer |
| Glaxosmithkline, LLC. | $117.42 | 2023 | Arexvy |
| Steris Corporation | $101.16 | 2022 | |
| Dexcom, INC. | $96.80 | 2025 | Dexcom G6 Transmitter |
| Braintree Laboratories, INC. | $88.97 | 2019-2021 | |
| Ucb, INC. | $81.42 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $46.53 | 2025 | Panhematin |
| Capsovision, INC. | $46.46 | 2024 | Capsocam Plus |
| Alfasigma USA, INC. | $32.43 | 2020 | |
| Orphalan INC | $29.39 | 2025 | Cuvrior |
| Romark Laboratories, Lc | $27.82 | 2020 | |
| Shire North American Group INC | $24.89 | 2019 | |
| Shionogi INC | $24.41 | 2019 | |
| Biocon Biologics INC | $22.46 | 2025 | Yesintek |
| Tersera Therapeutics LLC | $19.42 | 2021 | |
| Shield Therapeutics INC | $18.29 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,800.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatachala Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.